Healthcare provider profile · identity verified

Brandy Maxine Allen, MD

Internal Medicine · DENVER, CO · NPI 1609865468

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	559	159
Levothyroxine Sodium	Levothyroxine Sodium	378	109
Amlodipine Besylate	Amlodipine Besylate	308	93
Lisinopril	Lisinopril	293	90
Simvastatin	Simvastatin	289	80
Losartan Potassium	Losartan Potassium	266	81
Omeprazole	Omeprazole	263	95
Metformin Hcl	Metformin Hcl	217	69
Alendronate Sodium	Alendronate Sodium	167	52
Tramadol Hcl	Tramadol Hcl	146	30
Rosuvastatin Calcium	Rosuvastatin Calcium	145	51
Tamsulosin Hcl	Tamsulosin Hcl	140	45
Sertraline Hcl	Sertraline Hcl	126	39
Albuterol Sulfate Hfa	Albuterol Sulfate	116	67
Metoprolol Tartrate	Metoprolol Tartrate	114	36
Furosemide	Furosemide	107	38
Pradaxa	Dabigatran Etexilate Mesylate	105	37
Gabapentin	Gabapentin	104	34
Atenolol	Atenolol	103	29
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	91	28
Pantoprazole Sodium	Pantoprazole Sodium	86	29
Warfarin Sodium	Warfarin Sodium	83	23
Arexvy	Rsvpref3 Antigen/As01e/Pf	80	80
Fluoxetine Hcl	Fluoxetine Hcl	78	19
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	72	15
Potassium Chloride	Potassium Chloride	67	25
Hydrochlorothiazide	Hydrochlorothiazide	65	23
Mirtazapine	Mirtazapine	65	23
Duloxetine Hcl	Duloxetine Hcl	63	21
Allopurinol	Allopurinol	62	17
Wixela Inhub	Fluticasone Propion/Salmeterol	61	18
Metoprolol Succinate	Metoprolol Succinate	58	17
Glipizide	Glipizide	57	21
Trazodone Hcl	Trazodone Hcl	56	21
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	52	52
Citalopram Hbr	Citalopram Hydrobromide	52	16
Famotidine	Famotidine	51	17
Estradiol	Estradiol	50	22
Clopidogrel	Clopidogrel Bisulfate	49	16
Bupropion Xl	Bupropion Hcl	48	16
Jardiance	Empagliflozin	48	13
Alvesco	Ciclesonide	47	21
Triamcinolone Acetonide	Triamcinolone Acetonide	47	28
Fluticasone Propionate	Fluticasone Propionate	43	22
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	43	13
Ezetimibe	Ezetimibe	40	14
Humulin N	Insulin Nph Human Isophane	39	13
Metformin Hcl Er	Metformin Hcl	39	11
Eliquis	Apixaban	38	suppressed
Shingrix	Varicella-Zoster Ge/As01b/Pf	38	35
Meloxicam	Meloxicam	37	16
Venlafaxine Hcl Er	Venlafaxine Hcl	35	12
Finasteride	Finasteride	34	11
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	34	11
Acyclovir	Acyclovir	31	14
Doxazosin Mesylate	Doxazosin Mesylate	28	suppressed
Pravastatin Sodium	Pravastatin Sodium	27	suppressed
Solifenacin Succinate	Solifenacin Succinate	27	suppressed
Spiriva Respimat	Tiotropium Bromide	27	12
Trospium Chloride	Trospium Chloride	27	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	25	suppressed
Lovastatin	Lovastatin	25	suppressed
Carvedilol	Carvedilol	24	suppressed
Oxycodone Hcl	Oxycodone Hcl	23	suppressed
Morphine Sulfate Er	Morphine Sulfate	21	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	20	suppressed
Lorazepam	Lorazepam	19	suppressed
Ipratropium Bromide	Ipratropium Bromide	18	suppressed
Insulin Syringe	Syringe And Needle,insulin,1ml	17	suppressed
Azelastine Hcl	Azelastine Hcl	16	suppressed
Prednisone	Prednisone	16	16
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	15	suppressed
Hydralazine Hcl	Hydralazine Hcl	13	suppressed
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	13	suppressed
Repatha Sureclick	Evolocumab	13	suppressed
Ropinirole Hcl	Ropinirole Hcl	13	suppressed
Cefuroxime	Cefuroxime Axetil	12	12
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	12	suppressed
Ondansetron Odt	Ondansetron	11	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error